A thorough understanding of how proteins induce nanoparticle (NP) aggregation is crucial when designing in vitro and in vivo assays and interpreting experimental results. This knowledge is also crucial when developing nano-applications and formulation for drug delivery systems. In this study, we found that extraction of immunoglobulin G (IgG) from cow serum results in lower polystyrene NPs aggregation. Moreover, addition of isolated IgG or fibrinogen to fetal cow serum enhanced this aggregation, thus demonstrating that these factors are major drivers of NP aggregation in serum. Counter-intuitively, NP aggregation was inversely dependent on protein concentration; i.e., low protein concentrations induced large aggregates, whereas high protein concentrations induced small aggregates. Protein-induced NP aggregation and aggregate size were monitored by absorbance at 400 nm and dynamic light scattering, respectively. Here, we propose a mechanism behind the protein concentration dependent aggregation; this mechanism involves the effects of multiple protein interactions on the NP surface, surface area limitations, aggregation kinetics, and the influence of other serum proteins.
Introduction
Many nanoparticles have the tendency to aggregate in physiologically relevant buffers. This becomes a fundamental problem hindering systematic and reproducible studies of the characteristics and effects of nanoparticles. In physiological environments, there are usually large varieties of proteins in high concentrations, which can either stabilize nanoparticle (NP) dispersion or induce aggregation. Therefore, adding proteins to experimental systems can further complicate these studies. Thus, a thorough understanding of how proteins influence nanoparticles is necessary for evaluation of their effects regarding nanosafety and nanotoxicology and in the development of nano-applications for use in physiological environments. Nano Res. 2015, 8(8) : [2733] [2734] [2735] [2736] [2737] [2738] [2739] [2740] [2741] [2742] [2743] In a complex biological environment (e.g., human blood, lung fluid, or cell medium), proteins will-in competition with each other-bind to the NP surface, forming a protein corona [1] [2] [3] [4] [5] [6] [7] [8] [9] . The protein corona changes over time [2, 4, 10, 11] depending on the surrounding protein concentration [3, 12] and their affinities for the NP surface. The fate depends both on the size, charge and material of the NPs and which protein it interacts with; thus, isolated proteins may or may not induce NP aggregation.
No aggregation has been detected in previous studies using silica NPs mixed with human carbonic anhydrase, cytochrome C, or ribonuclease A [13] [14] [15] . The same trend has been observed for transferrin or serum albumin mixed with sulfonated polystyrene NPs [16, 17] , while other studies show that gold NPs are stabilized by serum albumin and cytochrome C [18] [19] [20] [21] . Lysozyme, however, can induce the strong aggregation of silica, polystyrene, and gold NPs [17, [22] [23] [24] [25] , which also is observed when fibrinogen is incubated with polystyrene and silica NPs [26] . Interestingly, fibrinogen induces aggregation of poly-(acrylic acid)-conjugated gold NPs [27] in a protein concentration-dependent manner. Titanium dioxide NPs can form large micrometer-sized aggregates in many protein-containing fluids [1] , while other metal oxides-Fe 2 O 3 , ZnO, and surface functionalized Fe 3 O 4 , for example-are instead stabilized by serum proteins [28] [29] [30] . Polystyrene NPs in blood plasma induce large, nanometer-sized complexes, probably consisting of proteins and multiple particles [3, 12] . Gold NPs induce large, nano-sized aggregates without indication of particle agglomeration [2, 5] , implying that proteins can serve as a link between particles. The aggregation of NPs in blood plasma or serum also depends on particle size, protein concentration, incubation time, and buffer composition [3, 5, 8, 9, 11, 12, 31, 32] .
Immunoglobulin G (IgG)-the second most abundant protein in human blood plasma and extracellular fluid-is an antibody isotype vital for immune system function. Here, it binds pathogens resulting in their immobilization and agglutination, coats the pathogen surfaces (opsonization) allowing their recognition and phagocytosis, activates the classical pathway of the complement system, and binds and neutralizes toxins. Despite its role in the immune system and importance in many medical applications, IgG is rarely used as a model protein in protein-NP interactions.
Knowledge of how different proteins affect NP aggregation is important when designing and interpreting any experiment that involves both proteins and nanoparticles, for example, protein binding, in vitro and in vivo assays, and formulation of medical delivery systems.
In this study, we investigated protein-induced NP aggregation and found that IgG induces NP aggregation in a counter-intuitive concentrationdependent manner and also drives NP aggregation in blood serum. This process is dependent on the NP material, the protein, and the environment.
Experimental

NPs and proteins
Polystyrene (PS) and polymethyl methacrylate (PMMA) NPs were purchased from Bangs Laboratories, Inc. (Fisher, IN, USA). Two PS NPs with different surface modifications were used: sulfonated (PS-OSO 3 H) and carboxylated (PS-COOH). The mean hydrodynamic diameter-measured by dynamic light scattering (DLS) using a Malvern Zeta NANO ZS (Malvern Instrument Limited, Malvern, UK) for PS-OSO 3 H and PS-COOH NPs is 27 nm (Table S1 and S2 in the Electronic Supplementary Material (ESM)). PS-OSO 3 H and PS-COOH NPs have a Zeta potential of around -45 mV [33] . Mannan nanogel was synthesized as previously described [34] with near neutral charge and mean hydrodynamic diameter of 154 nm. Human IgG was purchased from Lee Biosolutions (St. Louis, MO, USA). Fc and Fab fragments from human IgG were purchased from Meridian Life Science, Inc. (Memphis, TN, USA). Human fibrinogen and fatty acid free human serum albumin (HSA; A3782) were purchased from SigmaAldrich (St. Louis, MO, USA). The HSA monomer was purified from dimers and oligomers as previously described [17] . Different qualities of fibrinogen, with respect to purity, were tested and differing results were obtained for these: F4883: 35%-65% protein, ≥90% which is clottable; or F3879: 50%-70% protein, ≥80% of protein is clottable. Both were purchased from Sigma-Aldrich. The presented data is from 
IgG purification
Bovine IgG was purified from cow serum, (Innovative research, IBV-SER) using affinity chromatography on Pierce Protein A/G Plus Agarose column (Fisher Scientific AB, 20423; Fisher Scientific AB, Waltham, MA, USA). The cow serum was filtered through a 1.2-μm filter before it was added to the PBS-washed column (Fig. S1 , step 1, in the ESM) and incubated at room temperature for 25-30 min (Fig. S1 , step 2, in the ESM). Thereafter, the cow serum was collected (same volume as was applied to the column) and non-IgG material was washed with PBS until A 280 was close to zero (Fig. S1, step 3 , in the ESM). Then, 0.1 M glycine pH 2.5 was applied to dissociate the Protein A/G-IgG interaction and the eluate was collected into tubes containing 1 M Tris-HCl pH 8.8 (120 μL/1 mL fraction) (Fig. S1, step 4 , in the ESM). The tubes were monitored at A 280 and the fractions containing IgG with highest absorbance was pooled and dialyzed against PBS ( Fig. S2(a) in the ESM). The cow serum eluted after incubation was applied to the column for a second time and the same purification procedure was repeated (Fig. S1 , step 1-4, in the ESM). SDS-PAGE was used to characterize the cow serum before and after IgG was removed and also to assess the IgG purity. The samples were incubated and heated at 95 °C with mercaptoethanol before loading on the gel (Fig. S2(b) in the ESM).
Aggregation measured by UV spectroscopy
NP aggregation was monitored by measuring absorbance at 400 nm on an UV-1800 UV spectrometer (Shimadzu, Japan). At this wavelength, the turbidity of the sample is measured (i.e. how much light is scattered by particles in the solution). At the concentrations used, neither NPs nor proteins absorbed significantly at 400 nm. However, some absorbance was recorded at high protein concentrations. This value was subtracted from that of the formed aggregates.
Before measurements were taken, 150 μL of NPs PS-OSO 3 H, PS-COOH, PMMA, or mannan nanogel at a concentration of 1 or 0.5 mg/mL were mixed with 1.35 mL IgG, HSA, a mixture of HSA/IgG, IgG Fc fragments, IgG Fab fragments, fibrinogen, or lysozyme. The protein concentrations varied between 0.005 and 5 mg/mL, as indicated in the tables and figures. Aggregation in cow serum or fetal calf serum (FCS) was achieved by mixing serum dilutions with PS-OSO 3 H. In some experiments, IgG was added to the FCS before adding NPs. The final concentration of serum, added IgG, and NPs are indicated in the text and figure labels. The mixtures were incubated for at least 1 h before the absorbance was monitored at 400 nm. The experiments were performed in at least triplicates. The same conditions were used for kinetics experiments, but the absorbance at 400 nm was measured immediately, with a lag time of 5 to 10 s, and then every 5 s for 10 to 20 min. The time at which half of the aggregation was completed, as measured by the absorbance, was determined by fitting the equation
where Abs is the absorbance at 400 nm, Abs 0 is the absorbance at 400 nm at time zero, Abs max is the absorbance at 400 nm when the steady state is reached, t is the time in seconds, and t 1/2 is the time in seconds when half of the reaction is completed.
Size of the aggregates measured with DLS
The hydrodynamic diameter of NPs and protein/NP mixtures was determined by DLS using a Malvern Zeta NANO ZS. NaCl, pH 7.4. The NP size was the same in both buffers (data not shown).
Circular dichroism (CD) spectroscopy and intrinsic tryptophan fluorescence spectroscopy
Different concentrations of PS-OSO 3 H, PS-COOH, or mannan nanogel diluted in PBS with 0.1 mM EDTA were mixed with proteins dissolved in the same solution. NPs were added to the protein solution and incubated for 30 ± 5 min before recording spectra. The CD signal was recorded between 260 and 200 nm in a quartz (QS) cuvette with 1 mm path length at 37 °C using a Jasco J-815 CD spectrometer (Jasco Analytical Instruments, Easton, MD, USA). The scanning rate was 50 nm/min, the digital integration time per data point (DIT) was 8 s, and the data collected were from an average of five accumulations. The fluorescence emission spectrum was recorded at 37 °C in 10 or 3 mm QS cuvettes using a Perkin-Elmer LS 50 B luminescence spectrometer (Perkin-Elmer, Waltham, MA, USA) between 310 and 420 nm after excitation at 290 nm at a scan rate of 50 nm/min. The excitation and emission slits were set to 3 nm. The data collected was from an average of three accumulations and the background signal from the NPs was subtracted from the overall read. Samples were handled in the same way as in the CD spectroscopy experiments.
Identical NPs titrations into protein-free buffer, PBS with 0.1 mM EDTA were performed, and the CD and fluorescence signals were recorded. In the case of fluorescence, these data were used for baseline subtraction from the protein-NPs data. Typically, the CD signal-to-noise ratio was higher in the presence than in the absence of proteins. Therefore, the CD results are reported without subtracting the background signal.
Light microscopy
Aggregates were imaged in a clear 96-well plate (Nunc, Rochester, NY, USA) using an Olympus IX71 microscope (Olympus, Tokyo, Japan). Images were acquired using Olympus cellSens digital imaging software.
Results and discussion
To investigate if IgG was responsible for inducing NP aggregation in blood serum, PS-OSO 3 H NPs were incubated in FCS, cow serum, or cow serum depleted of bovine IgG by affinity chromatography (Fig. S1 in the ESM). If IgG is responsible for NP aggregation, less aggregation would be expected in FCS as compared to that for cow serum and cow serum without IgG. FCS was selected because the biological impact of NPs is often evaluated by studying human cell cultures with FCS in the growth medium. Indeed, strong aggregation was seen in diluted cow serum, with less aggregation observed in IgG-depleted cow serum as monitored by measuring the absorbance at 400 nm ( Fig. 1(a) ). Strikingly, no aggregation was seen in FCS, regardless the serum concentration ( Fig. 1(a) ). This demonstrated that NP aggregation in cow serum decreased as the serum concentration increased, indicating that other proteins or biomolecules might inhibit NP aggregation in high serum concentrations. Thus, many problems experienced in cell experiments performed at low serum concentrations may be absent in full blood. Increasing the NPs concentration in 1% serum revealed that the aggregation is clearly particle concentration-dependent ( Fig. 1(b) ). Cow serum induced highest NP aggregation at all concentrations, and FCS lowest, whereas IgG-depleted cow serum yielded an intermediate aggregation. Adding isolated bovine IgG to FCS and IgG-depleted cow serum restored this aggregation (Fig. 1(c) ). These results strongly indicate that IgG is an important factor driving PS-OSO 3 H aggregation in serum. Therefore, NP aggregation with isolated bovine IgG was investigated. As shown in Fig. 1(d) , NP aggregation is dependent on the protein concentration. Samples at different IgG:NP ratios were also imaged with light microscopy (Fig. S3 in the ESM) . At low absorbance (NP only, few or many IgG/NP) no or few small visible aggregates were observed (Figs. S3(a)-S3(c) and S3(f) in the ESM), whereas visible aggregates become more pronounced at higher absorbance (Figs. S3(d) and S3(e) in the ESM). This corresponds to the absorbance profiles at 400 nm ( Fig. 1(d) ).
Next, we investigated IgG-driven NP aggregation
in detail in PBS. Human IgG is used for the following experiments. In addition to PS-OSO 3 H, we also used PS-COOH NPs, which have different surface groups but both are negatively charged at pH 7.5. PS-OSO 3 H or PS-COOH NPs were mixed with increasing concentrations of IgG (Fig. 2) . The absorbance increases at around 5 to 10 IgG molecules per NP, indicative of aggregate formation (Figs. 2(a) and 2(b) ). Further increases in the number of IgG molecules failed to elicit any significant differences in absorbance until a minimum of 40 to 100 molecules was reached. Above 100 IgG molecules per NP, the absorbance decreases and the solutions become transparent, indicating that no or small aggregates formed. These results reveal an inverse correlation between the number of IgG molecules in the solution and the degree of aggregation, which is similar to the aggregation behavior observed with isolated bovine IgG ( Fig. 1(d) ). Increasing the particle concentration two-fold resulted in a similar aggregation profile (Figs. 2(a) and 2(b)). To investigate if the structural change of IgG was causing the NP aggregation, the secondary and tertiary structure were monitored with CD and intrinsic tryptophan fluorescence spectroscopy, respectively. Changes in the tertiary structure were observed, seen as a decrease in intensity, but no shift in the tryptophan emission was detected. The secondary structure, however, was slightly affected when IgG bound to the NPs (Fig. S4 in the ESM). This data implies that IgG denaturation was not required for the aggregation to occur. To determine the size of the PS-OSO 3 H:IgG complexes, DLS was studied at various IgG concentrations (Fig. 2(c) and Table S1 in the ESM). At 2.8 IgG molecules per NP, the hydrodynamic diameter of the PS-OSO 3 H:IgG complexes was approximately 50 nm, indicating formation of small aggregates. At 28 IgG molecules per NP, the diameter reached over 2,000 nm, denoting large aggregates of multiple NPs and IgG molecules. At 112 IgG molecules per NP, the diameter is 128 nm and the highest absorbance was observed. This discrepancy between absorbance and DLS data can likely be explained by a large number of aggregates. The correlation between the observed absorbance and the increase in aggregation is not straightforward. Aggregates will scatter light resulting in an increase in the apparent absorbance, which increases exponentially with aggregate size. Therefore, an increase in the number of aggregates or in the size of aggregates will change the observed absorbance differently. At 560 IgG molecules per NP, two peaks corresponding to 15 and 70 nm in diameter, where the smaller probably represents unbound IgG. DLS data (Fig. 2(d) and Table S2 in the ESM) of PS-COOH confirms that this IgG-driven aggregation is similar to the one observed with PS-OSO 3 H NPs.
A possible explanation behind the IgG-induced aggregation is that IgG acts or serves as a protein bridge between NPs to form large aggregates. However, bridging can only occur if there is more than one surface to which IgG can bind. NP aggregation (Fig. S7 in the ESM) . A large excess of Fab could likely induce a small amount of aggregation, probably due to Fc impurities in the Fab preparation (data not shown). This implies that the NP aggregation is not driven by major structural changes.
PMMA NPs likewise aggregate with increasing concentrations of IgG (Fig. S8 in the ESM) . Interestingly, the aggregation profile is similar to those obtained with PS-OSO 3 H and PS-COOH. In contrast, IgG failed to induce the aggregation of mannan nanogel (data not shown). However, the changes in CD and mainly in the intrinsic tryptophan fluorescence spectra of IgG after the addition of mannan nanogel strongly indicated that IgG bound to the nanogel (Fig. S9 in the ESM), does not automatically result in particle aggregation.
The NP aggregation induced by fibrinogen is, as for IgG, dependent on the protein concentration ( Fig. 3(a) ). In contrast to IgG, there are large structural changes in fibrinogen that occur after binding to the NPs (Fig. S10 in the ESM) . DLS data show that the mean hydrodynamic diameter of the formed aggregates follows the same pattern as for IgG (Table S3 in the ESM). Large aggregates form at low fibrinogen concentrations but, at high fibrinogen concentrations, the size of the PS-OSO 3 H:fibrinogen complex is about 75 nm. Adding fibrinogen to FCS also induces the strong aggregation of PS-OSO 3 H NPs (Fig. 3(b) ). The fibrinogen concentration in serum is close to 3 mg/mL in plasma and uncoagulated blood; therefore, fibrinogen together with IgG is probably the primary driver of NP aggregation in blood. The same concentration dependent fibrinogen-induced aggregation in buffer was previously shown for polyacrylic acidconjugated gold NPs [27] . The authors suggest that when there is an excess of particle surface, fibrinogen acts as a bridge between them to form large aggregates but, when there is an excess of fibrinogen, the NP surface is rapidly covered by protein to prevent bridging between the NPs.
Our data on the IgG-driven aggregation of PS-OSO 3 H, PS-COOH, and PMMA NPs supports the proposed mechanism. We suggest that the important features of protein concentration-dependent aggregation can be described by considering four regimes (Scheme 2). In the first regime, there is a large excess of NPs resulting in a mixture of empty NPs, NPs with one IgG, and small aggregates where IgG functions as a bridge between two NPs. In the second regime, there are more IgG molecules per NP but still an excess of NP surface; therefore, one IgG molecule already bound to a NP can still bind to more than one NP and bridging can occur in many different directions to generate large aggregates. In the third, there is less available surface area and finding an empty area on a second NP for IgG to bind will take longer time, and therefore more smaller aggregates form. In the fourth regime, there is a large excess of IgG, leading to a decrease in aggregation because the NP surface becomes rapidly covered by IgG. Thus, at very high protein concentrations, no particle aggregation occurs since single particles are quickly covered by a protein monolayer. The described mechanism can be validated with two predictions. First, reducing the available surface area should decrease the size of the aggregates. As shown above, the NP aggregation is lower in high concentrations of blood serum than that in low concentrations (Fig. 1 ). This indicates that there are substances in serum that inhibit NP aggregation, which implies that the first prediction is correct. Albumin is a likely candidate, as it is the most abundant protein in blood serum, binds to PS-OSO 3 H and PS-COOH [17] , and cannot by itself induce particle aggregation (data not shown). Indeed, adding HSA to the PS-COOH NP before adding IgG reduces the NP absorbance (Fig. 4(a) ) and the diameter of the formed aggregates (Fig. 4(b) ) compared to that with IgG alone. Interestingly, the aggregation profile is still dependent on the IgG concentrations (Fig. 4(c) ). The order of adding HSA and IgG to the NPs is important since adding the same amount of HSA to IgG prior to adding PS-COOH NPs to the protein mixture increases the absorbance compared to first adding HSA to the particles (Fig. 4(d) ). This implies that the system is kinetically, rather than thermodynamically, driven over the time period of our experiments. Another way to reduce the surface area is to keep the added mass and increase the NP size. The addition of same amount of IgG to 60 nm PS-COOH NPs shifts the aggregation profile compared to 26 nm NPs (Fig. S11 in the ESM) . As expected, less (Fig. S11(a) in the ESM) as the total surface area is smaller. Furthermore, the number of IgG per NP needed to reduce the aggregation is higher since the surface area per NP is larger (Fig. S11(b) in the ESM). These experiments further strengthen the importance of the relationship between available surface area and the IgG-driven aggregation.
The second prediction is that the kinetics of the formation of larger aggregates should become retarded with increasing IgG concentrations. To verify this, the aggregation kinetics of PS-OSO 3 H and PS-COOH NPs mixed with IgG were studied by following the absorbance over time at 400 nm. Note that the aggregation process is followed for 1,200 s compared to 1 h or more in the previous measurements, and is the main reason why the absorbance might differ at the same IgG:NP ratios between the experiments. The lag time between mixing and the first reading is about 5 s. Examples of interesting differences in kinetics are shown in Figs. 5(a) and 5(b). The time point at which half of the process in this time range is completed, t 1/2 , was extracted from Eq. (1) by fitting that function to the experimental data (Figs. 5(c) and 5(d)). At IgG concentrations corresponding to 10 to 50 IgG molecules per NP, the aggregation was fast. Adding more IgG decreases the aggregation rate indicating that the second prediction is correct, (i.e., the kinetics of the aggregate formation slows down as the available surface area becomes limited). However, at the highest IgG concentrations, the aggregation rate increases again probably because only small aggregates of one or few particles rapidly forms (see regime 4 in Scheme 2). Note that the low absorbance makes it difficult to estimate the t 1/2 of aggregation at high IgG concentrations.
In the last few years, attention has been drawn to the protein corona that forms around NPs. Studying the protein corona may seem to be a straightforward project. However, the aggregation profile of IgG and fibrinogen highlights the need for caution. When the NPs aggregate into large complexes in protein-rich fluid, there will be many protein bridges that form strongly associated aggregates. Other proteins with Monoclonal antibodies (mAb) are used as active compounds in many biopharmaceutical drugs and are formulated either as liquids or as lyophilized products. In recent years, there has been a considerable research interest in the area of drug delivery of mAbs using NPs. Formulating the mAb together with NPs may provide for drug delivery at a controlled and sustained rate and, consequently improve the pharmacokinetic and pharmacodynamic properties of the compound. A potential challenge with mAb/NP formulations is that the NPs may form particle-particle aggregates, and potentially NP-mAb aggregates. It is a regulatory demand to minimize aggregates in biopharmaceutical drug products since they may cause safety problems, such as immunogenicity. In this report, we have shown that concentration-dependent IgG/NP-induced aggregation may be counter-intuitive. Although only a few NPs were investigated here, it is not unlikely that a similar behavior is observed in biopharmaceutical mAb/NP systems also. If so, this finding may have implications for future mAb/NP formulation development.
